Alina Errerd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alina Errerd has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Anna Rita Cantelmo
Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
2 shared publications - Evan Courmont
Université de Lille, Inserm, CHU Lille, Institut Pasteur de Lille
2 shared publications - Louay Bettaieb
Université de Lille, Inserm, CHU Lille, Institut Pasteur de Lille
2 shared publications Aleksandar Beatovic
Unicle Biomedical Data Science, Leuven, Belgium
1 shared publication- Alessandra Fiorio Pla
Department of Life Sciences and Systems Biology, University of Torino, via Accademia Albertina 13, 10123 Turin, Italy
1 shared publication - Alicia Mayeuf-Louchart
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
1 shared publication
Latest Publications
- Open Access
- 14 November 2026
- Published by Global Consulting INC in Cancer Biome and Targeted Therapy
- p. 81-126
Targeting Metabolic Heterogeneity in the Tumor Microenvironment: From Metabolic Plasticity to Therapeutic Vulnerability
Metabolic heterogeneity has emerged as a defining feature of cancer, yet its origins and therapeutic implications are often considered in a cancer cell-centric manner. Here, we summarize evidence that metabolic diversity is instead dynamically co-regulated by cancer cells, stromal and immune compartments, and by the abnormal vasculature within the tumor microenvironment (TME). We discuss how spatial and temporal fluctuations in oxygen and nutrient availability generate distinct metabolic niches that select for phenotypic plasticity and adaptive cell states. Across these niches, cancer cells differentially engage glycolysis, oxidative phosphorylation (OXPHOS), glutamine and lipid metabolism, and stress-response pathways, generating metabolic states associated with proliferation, survival, metastatic capacity, and therapy resistance. Particular attention is given to tumor endothelial cells (TECs), whose metabolic states influence vascular function and nutrient distribution and may thereby contribute to intratumoral metabolic heterogeneity. In parallel, oncogenic mutations, tissue context, and treatment-induced stress remodel pathway usage and foster the emergence of metabolically adaptable, stem-like, and drug-tolerant populations. Thus, cancer metabolic heterogeneity is shaped by cellular and environmental crosstalk rather than as a static consequence of genetic variation alone. This framework has important translational implications: effective metabolic therapies will require context-aware strategies that target specific niche liabilities while accounting for vascular state, immune function, and adaptive rewiring. Defining when and where these metabolic states create selective dependencies will be essential for translating metabolic heterogeneity into therapeutically actionable vulnerabilities.
- 14 November 2026
- Published by Global Consulting INC in Cancer Biome and Targeted Therapy
- p. 81-126
Open AccessTargeting Metabolic Heterogeneity in the Tumor Microenvironment: From Metabolic Plasticity to Therapeutic Vulnerability
Metabolic heterogeneity has emerged as a defining feature of cancer, yet its origins and therapeutic implications are often considered in a cancer cell-centric manner. Here, we summarize evidence that metabolic diversity is instead dynamically co-regulated by cancer cells, stromal and immune compartments, and by the abnormal vasculature within the tumor microenvironment (TME). We discuss how spatial and temporal fluctuations in oxygen and nutrient availability generate distinct metabolic niches that select for phenotypic plasticity and adaptive cell states. Across these niches, cancer cells differentially engage glycolysis, oxidative phosphorylation (OXPHOS), glutamine and lipid metabolism, and stress-response pathways, generating metabolic states associated with proliferation, survival, metastatic capacity, and therapy resistance. Particular attention is given to tumor endothelial cells (TECs), whose metabolic states influence vascular function and nutrient distribution and may thereby contribute to intratumoral metabolic heterogeneity. In parallel, oncogenic mutations, tissue context, and treatment-induced stress remodel pathway usage and foster the emergence of metabolically adaptable, stem-like, and drug-tolerant populations. Thus, cancer metabolic heterogeneity is shaped by cellular and environmental crosstalk rather than as a static consequence of genetic variation alone. This framework has important translational implications: effective metabolic therapies will require context-aware strategies that target specific niche liabilities while accounting for vascular state, immune function, and adaptive rewiring. Defining when and where these metabolic states create selective dependencies will be essential for translating metabolic heterogeneity into therapeutically actionable vulnerabilities.
- Open Access
makeTCR: A Modular Platform for Rapid, Flexible, Scalable, Single-Step T Cell Receptor Synthesis
Personalised cell therapies utilising T cell receptors (TCRs) show tremendous clinical promise, though TCR synthesis and validation techniques lag behind our ability to sequence TCR repertoires. To address this gap, we developed makeTCR: a flexible modular, scalable TCR cloning system that enables single-step, 100% fidelity assembly of αβ and γδ TCRs into commonly used expression vectors. By implementing cell-free manufacturing, makeTCR enables patient-derived TCRs to be functionally validated within 48 hours. We provide an open-source, easily extensible, web-based graphical platform that integrates existing tools to simplify and standardise the manufacture of TCRs across all scales of synthesis.
Open AccessmakeTCR: A Modular Platform for Rapid, Flexible, Scalable, Single-Step T Cell Receptor Synthesis
Personalised cell therapies utilising T cell receptors (TCRs) show tremendous clinical promise, though TCR synthesis and validation techniques lag behind our ability to sequence TCR repertoires. To address this gap, we developed makeTCR: a flexible modular, scalable TCR cloning system that enables single-step, 100% fidelity assembly of αβ and γδ TCRs into commonly used expression vectors. By implementing cell-free manufacturing, makeTCR enables patient-derived TCRs to be functionally validated within 48 hours. We provide an open-source, easily extensible, web-based graphical platform that integrates existing tools to simplify and standardise the manufacture of TCRs across all scales of synthesis.
- Open Access
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eadp6182
Integrated single-cell RNA-seq analysis reveals mitochondrial calcium signaling as a modulator of endothelial-to-mesenchymal transition
Endothelial cells (ECs) are highly plastic, capable of differentiating into various cell types. Endothelial-to-mesenchymal transition (EndMT) is crucial during embryonic development and contributes substantially to vascular dysfunction in many cardiovascular diseases (CVDs). While targeting EndMT holds therapeutic promise, understanding its mechanisms and modulating its pathways remain challenging. Using single-cell RNA sequencing on three in vitro EndMT models, we identified conserved gene signatures. We validated original regulators in vitro and in vivo during embryonic heart development and peripheral artery disease. EndMT induction led to global expression changes in all EC subtypes rather than in mesenchymal clusters. We identified mitochondrial calcium uptake as a key driver of EndMT; inhibiting mitochondrial calcium uniporter (MCU) prevented EndMT in vitro, and conditional Mcu deletion in ECs blocked mesenchymal activation in a hind limb ischemia model. Tissues from patients with critical limb ischemia with EndMT features exhibited significantly elevated endothelial MCU. These findings highlight MCU as a regulator of EndMT and a potential therapeutic target.
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eadp6182
Open AccessIntegrated single-cell RNA-seq analysis reveals mitochondrial calcium signaling as a modulator of endothelial-to-mesenchymal transition
Endothelial cells (ECs) are highly plastic, capable of differentiating into various cell types. Endothelial-to-mesenchymal transition (EndMT) is crucial during embryonic development and contributes substantially to vascular dysfunction in many cardiovascular diseases (CVDs). While targeting EndMT holds therapeutic promise, understanding its mechanisms and modulating its pathways remain challenging. Using single-cell RNA sequencing on three in vitro EndMT models, we identified conserved gene signatures. We validated original regulators in vitro and in vivo during embryonic heart development and peripheral artery disease. EndMT induction led to global expression changes in all EC subtypes rather than in mesenchymal clusters. We identified mitochondrial calcium uptake as a key driver of EndMT; inhibiting mitochondrial calcium uniporter (MCU) prevented EndMT in vitro, and conditional Mcu deletion in ECs blocked mesenchymal activation in a hind limb ischemia model. Tissues from patients with critical limb ischemia with EndMT features exhibited significantly elevated endothelial MCU. These findings highlight MCU as a regulator of EndMT and a potential therapeutic target.